Cooley LLP announced today that it advised Xencor, Inc. on its initial public offering. Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, now trades on the NASDAQ Global Market under the symbol “XNCR.”
The Cooley corporate securities team advising Xencor was led by partners Tom Coll and Ken Rollins and included associates James Pennington, Karen Deschaine, Kristin VanderPas, Rebecca Jones, Terren O’Connor and Matt Robbins. Critical support for the offering was provided by partners Natasha Leskovsek and Drew Gantt, and associate David Sclar (regulatory); associate Megan Arthur (compensation and benefits); and partners Bill Morrow and Mark Hrenya (tax).
Related Posts:
- Cooley Advises Ambit on its Initial Public Offering
- Cooley Advises Underwriters on Five Prime Therapeutics IPO
- Cooley Advises Kite Pharma on $146 Million Initial Public Offering
- Cooley Advises Underwriters on Receptos, Inc. Initial Public Offering
- Cooley Advises Underwriters on HealthEquity’s $146.5 Million IPO
